|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EIF4EBP3 |
Gene summary for EIF4EBP3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EIF4EBP3 | Gene ID | 8637 |
| Gene name | eukaryotic translation initiation factor 4E binding protein 3 | |
| Gene Alias | 4E-BP3 | |
| Cytomap | 5q31.3 | |
| Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | O60516 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8637 | EIF4EBP3 | P21T-E | Human | Esophagus | ESCC | 1.26e-53 | 9.22e-01 | 0.1617 |
| 8637 | EIF4EBP3 | P23T-E | Human | Esophagus | ESCC | 2.13e-63 | 1.29e+00 | 0.108 |
| 8637 | EIF4EBP3 | P24T-E | Human | Esophagus | ESCC | 2.06e-19 | 4.92e-01 | 0.1287 |
| 8637 | EIF4EBP3 | P28T-E | Human | Esophagus | ESCC | 6.83e-09 | 2.08e-01 | 0.1149 |
| 8637 | EIF4EBP3 | P30T-E | Human | Esophagus | ESCC | 3.04e-16 | 5.01e-01 | 0.137 |
| 8637 | EIF4EBP3 | P31T-E | Human | Esophagus | ESCC | 4.29e-41 | 7.03e-01 | 0.1251 |
| 8637 | EIF4EBP3 | P32T-E | Human | Esophagus | ESCC | 1.92e-14 | 4.21e-01 | 0.1666 |
| 8637 | EIF4EBP3 | P36T-E | Human | Esophagus | ESCC | 1.80e-32 | 9.73e-01 | 0.1187 |
| 8637 | EIF4EBP3 | P37T-E | Human | Esophagus | ESCC | 2.88e-04 | 1.29e-01 | 0.1371 |
| 8637 | EIF4EBP3 | P38T-E | Human | Esophagus | ESCC | 4.17e-18 | 6.84e-01 | 0.127 |
| 8637 | EIF4EBP3 | P39T-E | Human | Esophagus | ESCC | 3.43e-09 | 2.45e-01 | 0.0894 |
| 8637 | EIF4EBP3 | P40T-E | Human | Esophagus | ESCC | 4.53e-04 | 1.26e-01 | 0.109 |
| 8637 | EIF4EBP3 | P42T-E | Human | Esophagus | ESCC | 4.31e-11 | 3.49e-01 | 0.1175 |
| 8637 | EIF4EBP3 | P44T-E | Human | Esophagus | ESCC | 2.31e-16 | 4.09e-01 | 0.1096 |
| 8637 | EIF4EBP3 | P47T-E | Human | Esophagus | ESCC | 9.46e-07 | 2.03e-01 | 0.1067 |
| 8637 | EIF4EBP3 | P48T-E | Human | Esophagus | ESCC | 5.95e-16 | 3.75e-01 | 0.0959 |
| 8637 | EIF4EBP3 | P49T-E | Human | Esophagus | ESCC | 5.23e-14 | 1.20e+00 | 0.1768 |
| 8637 | EIF4EBP3 | P52T-E | Human | Esophagus | ESCC | 1.95e-05 | 1.52e-01 | 0.1555 |
| 8637 | EIF4EBP3 | P54T-E | Human | Esophagus | ESCC | 1.10e-42 | 7.43e-01 | 0.0975 |
| 8637 | EIF4EBP3 | P56T-E | Human | Esophagus | ESCC | 1.10e-03 | 3.59e-01 | 0.1613 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000641727 | Esophagus | HGIN | regulation of translation | 139/2587 | 468/18723 | 1.46e-19 | 7.98e-17 | 139 |
| GO:000641320 | Esophagus | HGIN | translational initiation | 55/2587 | 118/18723 | 7.33e-18 | 2.31e-15 | 55 |
| GO:000644610 | Esophagus | HGIN | regulation of translational initiation | 34/2587 | 79/18723 | 2.09e-10 | 1.97e-08 | 34 |
| GO:00342496 | Esophagus | HGIN | negative regulation of cellular amide metabolic process | 66/2587 | 273/18723 | 2.74e-06 | 9.60e-05 | 66 |
| GO:00171486 | Esophagus | HGIN | negative regulation of translation | 59/2587 | 245/18723 | 1.03e-05 | 2.96e-04 | 59 |
| GO:00459475 | Esophagus | HGIN | negative regulation of translational initiation | 10/2587 | 19/18723 | 6.97e-05 | 1.59e-03 | 10 |
| GO:0006413110 | Esophagus | ESCC | translational initiation | 100/8552 | 118/18723 | 1.16e-18 | 1.25e-16 | 100 |
| GO:0006417111 | Esophagus | ESCC | regulation of translation | 304/8552 | 468/18723 | 1.53e-17 | 1.33e-15 | 304 |
| GO:000644617 | Esophagus | ESCC | regulation of translational initiation | 65/8552 | 79/18723 | 2.04e-11 | 7.07e-10 | 65 |
| GO:004594714 | Esophagus | ESCC | negative regulation of translational initiation | 16/8552 | 19/18723 | 6.45e-04 | 3.43e-03 | 16 |
| GO:003424914 | Esophagus | ESCC | negative regulation of cellular amide metabolic process | 144/8552 | 273/18723 | 1.08e-02 | 3.67e-02 | 144 |
| GO:000641722 | Liver | HCC | regulation of translation | 287/7958 | 468/18723 | 8.79e-17 | 8.08e-15 | 287 |
| GO:000641322 | Liver | HCC | translational initiation | 94/7958 | 118/18723 | 1.39e-16 | 1.24e-14 | 94 |
| GO:000644622 | Liver | HCC | regulation of translational initiation | 62/7958 | 79/18723 | 6.85e-11 | 2.48e-09 | 62 |
| GO:003424921 | Liver | HCC | negative regulation of cellular amide metabolic process | 144/7958 | 273/18723 | 3.80e-04 | 2.61e-03 | 144 |
| GO:001714821 | Liver | HCC | negative regulation of translation | 129/7958 | 245/18723 | 8.14e-04 | 4.87e-03 | 129 |
| GO:004594711 | Liver | HCC | negative regulation of translational initiation | 15/7958 | 19/18723 | 1.36e-03 | 7.28e-03 | 15 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EIF4EBP3 | SNV | Missense_Mutation | novel | c.269T>C | p.Ile90Thr | p.I90T | O60516 | protein_coding | tolerated(0.68) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| EIF4EBP3 | insertion | In_Frame_Ins | novel | c.235_243dupGAGGAGCTG | p.Glu79_Leu81dup | p.E79_L81dup | O60516 | protein_coding | TCGA-EA-A5ZF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | ||
| EIF4EBP3 | SNV | Missense_Mutation | c.193N>T | p.Pro65Ser | p.P65S | O60516 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| EIF4EBP3 | SNV | Missense_Mutation | rs368740046 | c.121G>A | p.Asp41Asn | p.D41N | O60516 | protein_coding | deleterious(0) | benign(0.033) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| EIF4EBP3 | SNV | Missense_Mutation | novel | c.191T>A | p.Ile64Asn | p.I64N | O60516 | protein_coding | deleterious(0) | possibly_damaging(0.884) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |